With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...
Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
Weight loss drugs like Ozempic, while transformative in combating obesity, have been linked to irreversible vision impairment ...
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
India Today on MSN2d
Benefits outweigh risks: Novo Nordisk India's MD on Ozempic side effectsVikrant Shrotriya, Novo Nordisk India's Managing Director, addressed concerns over the side effects of Ozempic during a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback